13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q2 2025 · Filed August 11, 2025 · Accession 0000950123-25-007471
Total Value
$82.1M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics, Inc. | GLUE | 5,652,922 | $25.5M | 31.04% |
| 2 | CRISPR Therapeutics AG | CRSP | 498,558 | $24.2M | 29.52% |
| 3 | Jade Biosciences, Inc. | JBIO | 1,525,820 | $15.2M | 18.56% |
| 4 | Skye Bioscience, Inc. | SKYE | 2,007,704 | $8.4M | 10.22% |
| 5 | Repare Therapeutics, Inc. | 760273102 | 2,646,657 | $3.7M | 4.48% |
| 6 | Contineum Therapeutics, Inc. | CTNM | 542,628 | $2.2M | 2.62% |
| 7 | Tempest Therapeutics, Inc. | TPST | 269,772 | $1.8M | 2.23% |
| 8 | Adverum Biotechnologies, Inc. | 00773U108 | 506,821 | $1.1M | 1.33% |